Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022)
Matteo Boattini(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Rossana Cavallo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Silvia Corcione(University of Turin), Francesco Giuseppe De Rosa(University of Turin), Cristina Costa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Sara Comini(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Gabriele Bianco(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Paulo Bastos, André Almeida(Hospital de Santa Marta)
European Journal of Clinical Microbiology & Infectious Diseases
November 21, 2023
Cited by 30
Related Papers
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage
|International Journal of Infectious Diseases|2020|75
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
|European Journal of Clinical Microbiology & Infectious Diseases|2021|51